Elevated serum soluble ST2 levels may predict the fatal outcomes in patients with chronic heart failure

被引：6
作者：
Yao, Heng-Chen [1 ,2 ]
Li, Xiao-Yun [3 ]
Han, Qian-Feng [2 ]
Wang, Lan-Hua [2 ]
Liu, Tao [2 ]
Zhou, Yan-Hong [2 ]
Zhang, Mei [1 ]
Wang, Le-Xin [4 ]
机构：
[1] Shandong Univ, Sch Med, Qilu Hosp, Dept Cardiol, Jinan 250012, Peoples R China
[2] Taishan Med Univ, Sch Clin, Liaocheng Peoples Hosp, Dept Cardiol, Liaocheng 252000, Peoples R China
[3] Shandong Univ Tradit Chinese Med, Affiliated Hosp, Dept Gen Internal Med, Jinan 250014, Peoples R China
[4] Charles Sturt Univ, Sch Biomed Sci, Wagga Wagga, NSW 2678, Australia
来源：
INTERNATIONAL JOURNAL OF CARDIOLOGY | 2015年 / 186卷
关键词：
Heart failure; ST2; N terminal pro-brain natriuretic peptide; High-sensitivity C-reactive protein; BIOMARKERS; PROTEIN; DISEASE; IL-33;
D O I：
10.1016/j.ijcard.2015.03.269
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：303 / 304
页数：2
相关论文
共 12 条
[1]   Soluble ST2 is associated with adverse outcome in patients with heart failure of ischaemic aetiology [J].
Broch, Kaspar ;
Ueland, Thor ;
Nymo, Stale H. ;
Kjekshus, John ;
Hulthe, Johannes ;
Muntendam, Pieter ;
McMurray, John J. ;
Wikstrand, John ;
Cleland, John G. ;
Aukrust, Pal ;
Gullestad, Lars .
EUROPEAN JOURNAL OF HEART FAILURE, 2012, 14 (03) :268-277
[2]   Toll/Interleukin-1 receptor member ST2 exhibits higher soluble levels in type 2 diabetes, especially when accompanied with left ventricular diastolic dysfunction [J].
Fousteris, Evangelos ;
Melidonis, Andreas ;
Panoutsopoulos, George ;
Tzirogiannis, Konstantinos ;
Foussas, Stefanos ;
Theodosis-Georgilas, Anastasios ;
Tzerefos, Stavros ;
Matsagos, Spiridon ;
Boutati, Eleni ;
Economopoulos, Theofanis ;
Dimitriadis, George ;
Raptis, Sotirios .
CARDIOVASCULAR DIABETOLOGY, 2011, 10
[3]   Increased serum HMGB1 level may predict the fatal outcomes in patients with chronic heart failure [J].
Liu, Tao ;
Zhang, De-Yong ;
Zhou, Yan-Hong ;
Han, Qian-Feng ;
Wang, Lan-Hua ;
Wu, Lei ;
Yao, Heng-Chen .
INTERNATIONAL JOURNAL OF CARDIOLOGY, 2015, 184 :318-320
[4]   Combined Use of the Novel Biomarkers High-Sensitivity Troponin T and ST2 for Heart Failure Risk Stratification vs Conventional Assessment [J].
Lupon, Josep ;
de Antonio, Marta ;
Galan, Amparo ;
Vila, Joan ;
Zamora, Elisabet ;
Urrutia, Agustin ;
Bayes-Genis, Antoni .
MAYO CLINIC PROCEEDINGS, 2013, 88 (03) :234-243
[5]   Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST-elevation myocardial infarction [J].
Sabatine, Marc S. ;
Morrow, David A. ;
Higgins, Luke J. ;
MacGillivray, Catherine ;
Guo, Wei ;
Bode, Christophe ;
Rifai, Nader ;
Cannon, Christopher P. ;
Gerszten, Robert E. ;
Lee, Richard T. .
CIRCULATION, 2008, 117 (15) :1936-1944
[6]   IL-33 and ST2 comprise a critical biomechanically induced and card ioprotective signaling system [J].
Sanada, Shoji ;
Hakuno, Daihiko ;
Higgins, Luke J. ;
Schreiter, Eric R. ;
McKenzie, Andrew N. J. ;
Lee, Richard T. .
JOURNAL OF CLINICAL INVESTIGATION, 2007, 117 (06) :1538-1549
[7]   IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines [J].
Schmitz, J ;
Owyang, A ;
Oldham, E ;
Song, YL ;
Murphy, E ;
McClanahan, TK ;
Zurawski, G ;
Moshrefi, M ;
Qin, JZ ;
Li, XX ;
Gorman, DM ;
Bazan, JF ;
Kastelein, RA .
IMMUNITY, 2005, 23 (05) :479-490
[8]   ST2: A novel remodeling biomarker in acute and chronic heart failure [J].
Shah R.V. ;
Januzzi Jr. J.L. .
Current Heart Failure Reports, 2010, 7 (1) :9-14
[9]  
Tang W H Wilson, 2011, Congest Heart Fail, V17, P105, DOI 10.1111/j.1751-7133.2011.00221.x
[10]   Temporal changes of soluble ST2 after cardiovascular interventions [J].
Willems, Sanne ;
Sels, Jan-Willem ;
Flier, Suzanne ;
Versteeg, Dik ;
Buhre, Wolfgang F. ;
de Kleijn, Dominique P. V. ;
Hoefer, Imo E. ;
Pasterkamp, Gerard .
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2013, 43 (02) :113-120
12